—

Viking Therapeutics Inc (VKTX) — Technical state

As of 2026-11-12 — re-computed nightly across the coverage universe. Closelooknet diary readings, not advice.

The Closelooknet read

  • Closelooknet score: 28 out of 100 (momentum 25 · quality 2), as of 2026-11-14.
  • Signal: Stochastic turned down — Its stochastic crossed down from overbought (%K 70.2 under %D 77.8) today — momentum is cooling. (as of 2026-11-12)
  • Trend: Viking Therapeutics Inc trades 6.3% below its 50-day and 14.3% below its 200-day moving average. (as of 2026-11-12)
  • Index seat: HALO Growth 100

Viking Therapeutics is a clinical-stage biopharmaceutical company developing treatments for metabolic and endocrine disorders. Its lead programme is an oral thyroid hormone receptor beta agonist being tested against liver disease, alongside a selective androgen receptor modulator for post-fracture recovery and a dual GLP-1 agonist in early-stage trials.

The full read — the desk's view, the earnings record, peers and the company snapshot — is on the VKTX overview. Agents can buy the score depth per call over HTTP 402 — see the catalogue. Research diary readings, not advice.

Stochastic turned down

Its stochastic crossed down from overbought (%K 70.2 under %D 77.8) today — momentum is cooling.

The moving-average stack

FAQ · from the current data · as of 2026-11-12

Quick answers

What is the current Closelooknet signal on VKTX?

Stochastic turned down — Its stochastic crossed down from overbought (%K 70.2 under %D 77.8) today — momentum is cooling. As of 2026-11-12; the signal board re-computes across the coverage universe nightly. A research diary reading, not advice.

Is VKTX above its 50-day and 200-day moving averages?

As of 2026-11-12, Viking Therapeutics Inc trades -6.3% below its 50-day and -14.3% below its 200-day average, with the 20-day +4.2% away.

How far is VKTX from its 52-week high?

36.1% below the 52-week high and 15.8% above the 52-week low, as of 2026-11-12.

Related in the Closelooknet universe

same Closelooknet index seat first, then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.